Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 1.00 |
| ▸ | BCR | P11274 | 16/20 | 1.00 |
| ▸ | SRC | P12931 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | PRKACG | P22612 | 1/20 | 1.00 |
| ▸ | PRKACB | P22694 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 8/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.73 |
| ▸ | ABL2 | P42684 | 1/20 | 0.69 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | PRKCG | P05129 | 1/20 | 0.63 |
| ▸ | PRKCB | P05771 | 1/20 | 0.63 |
| ▸ | PRKCH | P24723 | 1/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823915 | 0.89 | CAMK2D (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4386919 | 0.88 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1789 | 0.86 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL3868291 | 0.85 | ABL1 (0.76) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2944432 | 0.85 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL29618427 | 0.84 | ABL1 (0.85) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4084867 | 0.84 | ABL1 (0.77) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL7461678 | 0.84 | ABL1 (0.73) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL6254782 | 0.84 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL7476769 | 0.84 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
| US-5516775-A | TO INHIBIT PROTEIN KINASE C | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | claimed |
| EP-0588762-A1 | Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs | CIBA-GEIGY AG (CH) | 1994-03-23 | — | — | EP | claimed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4129293-A1 | NERVE CELL DEGENERATION INHIBITOR | Kyoto University (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | DANA-FARBER CANCER INSTITUTE, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516775-A | TO INHIBIT PROTEIN KINASE C | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0588762-A1 | Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs | CIBA-GEIGY AG (CH) | 1994-03-23 | — | — | EP | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10969394-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | ABL1 1511/4885BCR 328/4885SRC 3188/4885 |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885SRC 796/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | ABL1 1511/4885BCR 328/4885SRC 3188/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885SRC 724/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885BCR 2315/4885SRC 3368/4885 |
| US-20210072254-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | ABL1 1511/4885BCR 328/4885SRC 3188/4885 |
| US-20190346454-A1 | Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes | PTMS, SRMS, HSP90B1 | ABL1 1511/4885BCR 328/4885SRC 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.